Bambusa Therapeutics
Transforming I&I Treatment with Next-Generation Bispecific Antibodies
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Business Model
- B2B
- Website
- bambusatx.com
- Total Funding
- $90.0M
- Last Round
- $90.0M Series AFeb 2025
About
Bambusa Therapeutics is developing next-generation bispecific antibodies for immunological and inflammatory (I&I) disorders, targeting conditions like atopic dermatitis, asthma, and COPD. The company's lead programs BBT001 and BBT002 use dual-pathway engineering to address the $40B+ Type 2 inflammatory dermatology market and the $80B+ Type 2 disorder market. Headquartered in Boston's Seaport district, Bambusa is backed by RA Capital, Janus Henderson, Redmile Group, and other leading life science investors.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account